Immunotherapy

Immunotherapy

Summary

immunotherapy is a therapeutic approach that modulates the immune system to improve anti-tumor responses, and in this entry it is used as a treatment context for outcome prediction in NSCLC. A clinician-deployable deep hypergraph model, deep hypergraph for nsclc, integrated clinical data and CT radiomics to predict immunotherapy outcomes in non-small cell lung cancer (NSCLC) (PMID:42008547). In a phase I clinical trial, direct immunotherapy injection into oral precancer lesions was associated with tumor shrinkage and no dose-limiting toxicities (PMID:42012894). Immunotherapy was also evaluated in combination with targeted therapy for prostate cancer, with the study assessing both efficacy and safety (PMID:42017392). Overall, the provided studies span predictive modeling, local intralesional delivery, and combination therapy, highlighting immunotherapy’s role across lung, oral precancer, and prostate cancer settings.

Key Findings

NSCLC

  • A clinician-deployable deep hypergraph model, deep hypergraph for nsclc, integrated clinical and CT radiomics to predict immunotherapy outcomes in NSCLC. (PMID:42008547)
  • The Key Facts indicate the model predicted immunotherapy outcomes, emphasizing its role as a therapy-context decision tool. (PMID:42008547)

Oral Precancer

  • Direct immunotherapy injection into oral precancer lesions produced tumor shrinkage in a phase I clinical trial. (PMID:42012894)
  • The trial reported no dose-limiting toxicities, supporting early safety for local delivery. (PMID:42012894)
  • The findings were reported in a 2026 Cancer Discovery study, indicating translational progress for intralesional immunotherapy. (PMID:42012894)

Prostate Cancer

  • Immunotherapy combined with targeted therapy was evaluated for efficacy and safety in prostate cancer. (PMID:42017392)
  • The study was published in a 2026 International Journal of Cancer report, reflecting ongoing combination-therapy assessment. (PMID:42017392)
  • This combination approach suggests immunotherapy is being explored beyond monotherapy in advanced cancer treatment strategies. (PMID:42017392)